Table 1.
Following VOE
|
Steady-state
|
|||
---|---|---|---|---|
Median (IQR) | n | Median (IQR) | n | |
Age | 16.5 (11–20) | 10 | 16 (10–19) | 9 |
Female sex, n (%) | 6 (60%) | 10 | 6 (60%) | 9 |
Quality of life: PedsQL™ Generic QoL inventory (total score)** | 68 (54.85–75) | 10 | 73.9 (63.04–80.43 | 9 |
SCD-specific quality of life: PedsQL™ SCD module (total score)** | 49.12 (41.86–63.41) | 10 | 62.2 (53.5–70.93) | 9 |
Pain Catastrophizing Scale | ||||
Total score | 30 (24–31) | 10 | 24 (19–29.5) | 8 |
Rumination | 12 (10–13) | 10 | 12 (10.5–15) | 8 |
Magnification | 6.5 (3–7) | 10 | 4.5 (3–6.5) | 8 |
Helplessness | 10.5 (8–11) | 10 | 7 (4.5–10) | 8 |
PROMIS measures (T-score) | ||||
Pain intensity* | 51.1 (49.4–58.3) | 10 | 43.2 (36.8–51.7) | 8 |
Pain interference^ | 59.1 (52.7–63.2) | 10 | 51.4 (49.5–56.05) | 8 |
Anxiety | 45.05 (43.9–58.4) | 10 | 44.75 (39.95–46.85) | 8 |
Depression | 51.5 (46–56.2) | 10 | 47.35 (45.05–51.5) | 8 |
Sleep disturbance^ | 56.5 (53.3–60) | 10 | 48.35 (46.4–51.15) | 8 |
Fatigue^ | 59.3 (55.3–63) | 10 | 49.25 (41.75–54.1) | 8 |
Notes:
0.05<p<0.1.
p<0.05.
p<0.01 (Wilcoxon signed-rank test used participants with data at two time points).
Abbreviations: SCD, sickle cell disease; VOE, vaso-occlusive episodes; IQR, interquartile range; PROMIS, Patient Reported Outcomes Measurement Information System.